Journal
JOURNAL OF NEUROSCIENCE
Volume 27, Issue 21, Pages 5766-5776Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.1004-07.2007
Keywords
excitotoxicity; neurodegenerative diseases; neuroinflammation; neuroprotection; peroxisome proliferator; activated receptor; thiadiazolidinones
Categories
Ask authors/readers for more resources
Inflammation and neurodegeneration coexist in many acute damage and chronic CNS disorders ( e. g., stroke, Alzheimer's disease, Parkinson's disease). A well characterized animal model of brain damage involves administration of kainic acid, which causes limbic seizure activity and subsequent neuronal death, especially in the CA1 and CA3 pyramidal cells and interneurons in the hilus of the hippocampus. Our previous work demonstrated a potent anti-inflammatory and neuroprotective effect of two thiadiazolidinones compounds, NP00111 ( 2,4-dibenzyl-[ 1,2,4] thiadiazolidine-3,5-dione) and NP01138 ( 2-ethyl-4-phenyl-[ 1,2,4] thiadiazolidine-3,5-dione), in primary cultures of cortical neurons, astrocytes, and microglia. Here, we show that injection of NP031112, a more potent thiadiazolidinone derivative, into the rat hippocampus dramatically reduces kainic acid-induced inflammation, as measured by edema formation using T-2-weighted magnetic resonance imaging and glial activation and has a neuroprotective effect in the damaged areas of the hippocampus. Last, NP031112-induced neuroprotection, both in vitro and in vivo, was substantially attenuated by cotreatment with GW9662 ( 2-chloro-5-nitrobenzanilide), a known antagonist of the nuclear receptor peroxisome proliferator-activated receptor gamma, suggesting that the effects of NP031112 can be mediated through activation of this receptor. As such, these findings identify NP031112 as a potential therapeutic agent for the treatment of neurodegenerative disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available